nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—atherosclerosis	0.128	0.529	CbGaD
Naproxen—ALB—atherosclerosis	0.114	0.471	CbGaD
Naproxen—UGT2B7—Ezetimibe—atherosclerosis	0.0553	0.103	CbGbCtD
Naproxen—UGT2B7—Simvastatin—atherosclerosis	0.0514	0.0958	CbGbCtD
Naproxen—UGT2B7—Lovastatin—atherosclerosis	0.0503	0.0937	CbGbCtD
Naproxen—UGT1A1—Ezetimibe—atherosclerosis	0.0478	0.089	CbGbCtD
Naproxen—UGT1A1—Simvastatin—atherosclerosis	0.0445	0.0828	CbGbCtD
Naproxen—UGT1A1—Lovastatin—atherosclerosis	0.0435	0.081	CbGbCtD
Naproxen—SLCO1A2—Rosuvastatin—atherosclerosis	0.0351	0.0653	CbGbCtD
Naproxen—SLCO1A2—Simvastatin—atherosclerosis	0.0326	0.0607	CbGbCtD
Naproxen—SLCO1A2—Pravastatin—atherosclerosis	0.0319	0.0594	CbGbCtD
Naproxen—SLCO1A2—Lovastatin—atherosclerosis	0.0319	0.0594	CbGbCtD
Naproxen—SLC22A6—Pravastatin—atherosclerosis	0.0194	0.0361	CbGbCtD
Naproxen—ALB—Rosuvastatin—atherosclerosis	0.0181	0.0338	CbGbCtD
Naproxen—CYP2C8—Simvastatin—atherosclerosis	0.013	0.0243	CbGbCtD
Naproxen—CYP2C8—Pravastatin—atherosclerosis	0.0128	0.0237	CbGbCtD
Naproxen—CYP2C8—Lovastatin—atherosclerosis	0.0128	0.0237	CbGbCtD
Naproxen—CYP2C9—Rosuvastatin—atherosclerosis	0.00977	0.0182	CbGbCtD
Naproxen—CYP2C9—Simvastatin—atherosclerosis	0.00909	0.0169	CbGbCtD
Naproxen—CYP2C9—Lovastatin—atherosclerosis	0.00889	0.0166	CbGbCtD
Naproxen—CYP2C9—Pravastatin—atherosclerosis	0.00889	0.0166	CbGbCtD
Naproxen—Indomethacin—PLA2G2A—atherosclerosis	0.000789	0.172	CrCbGaD
Naproxen—Ibuprofen—THBD—atherosclerosis	0.000584	0.128	CrCbGaD
Naproxen—PTGS2—leg—atherosclerosis	0.000535	0.105	CbGeAlD
Naproxen—Nabumetone—MPO—atherosclerosis	0.000486	0.106	CrCbGaD
Naproxen—PTGS2—hindlimb—atherosclerosis	0.000477	0.0938	CbGeAlD
Naproxen—PTGS2—appendage—atherosclerosis	0.00041	0.0805	CbGeAlD
Naproxen—Ibuprofen—PLAT—atherosclerosis	0.0004	0.0874	CrCbGaD
Naproxen—Indomethacin—PPARA—atherosclerosis	0.000338	0.0738	CrCbGaD
Naproxen—PTGS1—artery—atherosclerosis	0.000306	0.0602	CbGeAlD
Naproxen—PTGS2—artery—atherosclerosis	0.000293	0.0575	CbGeAlD
Naproxen—AKR1C3—adipose tissue—atherosclerosis	0.000265	0.0521	CbGeAlD
Naproxen—PTGS1—endothelium—atherosclerosis	0.000259	0.0508	CbGeAlD
Naproxen—PTGS2—endothelium—atherosclerosis	0.000247	0.0486	CbGeAlD
Naproxen—PTGS1—blood vessel—atherosclerosis	0.000238	0.0469	CbGeAlD
Naproxen—Indomethacin—CXCL8—atherosclerosis	0.000234	0.0511	CrCbGaD
Naproxen—PTGS2—blood vessel—atherosclerosis	0.000228	0.0448	CbGeAlD
Naproxen—UGT2B7—liver—atherosclerosis	0.000202	0.0396	CbGeAlD
Naproxen—Ketoprofen—CXCL8—atherosclerosis	0.000187	0.0409	CrCbGaD
Naproxen—AKR1C3—liver—atherosclerosis	0.000186	0.0365	CbGeAlD
Naproxen—Ibuprofen—CXCL8—atherosclerosis	0.000184	0.0403	CrCbGaD
Naproxen—Nabumetone—PTGS2—atherosclerosis	0.000182	0.0398	CrCbGaD
Naproxen—Carprofen—PTGS2—atherosclerosis	0.000174	0.038	CrCbGaD
Naproxen—UGT1A1—liver—atherosclerosis	0.000171	0.0337	CbGeAlD
Naproxen—Cardiac disorder—Pravastatin—atherosclerosis	0.000168	0.00131	CcSEcCtD
Naproxen—Muscle spasms—Simvastatin—atherosclerosis	0.000167	0.0013	CcSEcCtD
Naproxen—Vertigo—Lovastatin—atherosclerosis	0.000167	0.0013	CcSEcCtD
Naproxen—Angioedema—Ezetimibe—atherosclerosis	0.000167	0.0013	CcSEcCtD
Naproxen—Angiopathy—Niacin—atherosclerosis	0.000166	0.0013	CcSEcCtD
Naproxen—Leukopenia—Lovastatin—atherosclerosis	0.000166	0.0013	CcSEcCtD
Naproxen—Chills—Niacin—atherosclerosis	0.000165	0.00128	CcSEcCtD
Naproxen—Malaise—Ezetimibe—atherosclerosis	0.000164	0.00128	CcSEcCtD
Naproxen—Vision blurred—Simvastatin—atherosclerosis	0.000164	0.00128	CcSEcCtD
Naproxen—Arrhythmia—Niacin—atherosclerosis	0.000164	0.00128	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000163	0.00127	CcSEcCtD
Naproxen—Tremor—Simvastatin—atherosclerosis	0.000163	0.00127	CcSEcCtD
Naproxen—Alopecia—Niacin—atherosclerosis	0.000162	0.00126	CcSEcCtD
Naproxen—Chills—Pravastatin—atherosclerosis	0.000162	0.00126	CcSEcCtD
Naproxen—Insomnia—Rosuvastatin—atherosclerosis	0.000162	0.00126	CcSEcCtD
Naproxen—Indomethacin—PPARG—atherosclerosis	0.000162	0.0353	CrCbGaD
Naproxen—Ill-defined disorder—Simvastatin—atherosclerosis	0.000161	0.00126	CcSEcCtD
Naproxen—Arrhythmia—Pravastatin—atherosclerosis	0.000161	0.00126	CcSEcCtD
Naproxen—Palpitations—Ezetimibe—atherosclerosis	0.000161	0.00126	CcSEcCtD
Naproxen—Paraesthesia—Rosuvastatin—atherosclerosis	0.000161	0.00125	CcSEcCtD
Naproxen—Anaemia—Simvastatin—atherosclerosis	0.000161	0.00125	CcSEcCtD
Naproxen—Malnutrition—Niacin—atherosclerosis	0.00016	0.00124	CcSEcCtD
Naproxen—Erythema—Niacin—atherosclerosis	0.00016	0.00124	CcSEcCtD
Naproxen—Alopecia—Pravastatin—atherosclerosis	0.00016	0.00124	CcSEcCtD
Naproxen—Cough—Ezetimibe—atherosclerosis	0.000159	0.00124	CcSEcCtD
Naproxen—Angioedema—Simvastatin—atherosclerosis	0.000159	0.00124	CcSEcCtD
Naproxen—Arthralgia—Lovastatin—atherosclerosis	0.000158	0.00123	CcSEcCtD
Naproxen—Chest pain—Lovastatin—atherosclerosis	0.000158	0.00123	CcSEcCtD
Naproxen—Myalgia—Lovastatin—atherosclerosis	0.000158	0.00123	CcSEcCtD
Naproxen—Anxiety—Lovastatin—atherosclerosis	0.000158	0.00123	CcSEcCtD
Naproxen—Dyspepsia—Rosuvastatin—atherosclerosis	0.000158	0.00123	CcSEcCtD
Naproxen—Hypertension—Ezetimibe—atherosclerosis	0.000157	0.00123	CcSEcCtD
Naproxen—Flatulence—Niacin—atherosclerosis	0.000157	0.00123	CcSEcCtD
Naproxen—Malaise—Simvastatin—atherosclerosis	0.000157	0.00122	CcSEcCtD
Naproxen—Tension—Niacin—atherosclerosis	0.000157	0.00122	CcSEcCtD
Naproxen—Discomfort—Lovastatin—atherosclerosis	0.000156	0.00122	CcSEcCtD
Naproxen—Vertigo—Simvastatin—atherosclerosis	0.000156	0.00122	CcSEcCtD
Naproxen—Leukopenia—Simvastatin—atherosclerosis	0.000156	0.00121	CcSEcCtD
Naproxen—Arthralgia—Ezetimibe—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Chest pain—Ezetimibe—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Myalgia—Ezetimibe—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Nervousness—Niacin—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Flatulence—Pravastatin—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Dry mouth—Lovastatin—atherosclerosis	0.000155	0.00121	CcSEcCtD
Naproxen—Tension—Pravastatin—atherosclerosis	0.000154	0.0012	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000154	0.0012	CcSEcCtD
Naproxen—Muscle spasms—Niacin—atherosclerosis	0.000154	0.0012	CcSEcCtD
Naproxen—Discomfort—Ezetimibe—atherosclerosis	0.000153	0.0012	CcSEcCtD
Naproxen—Pain—Rosuvastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Naproxen—Constipation—Rosuvastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Naproxen—Confusional state—Lovastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Naproxen—Nervousness—Pravastatin—atherosclerosis	0.000153	0.00119	CcSEcCtD
Naproxen—Dry mouth—Ezetimibe—atherosclerosis	0.000152	0.00118	CcSEcCtD
Naproxen—Anaphylactic shock—Lovastatin—atherosclerosis	0.000152	0.00118	CcSEcCtD
Naproxen—Muscle spasms—Pravastatin—atherosclerosis	0.000151	0.00118	CcSEcCtD
Naproxen—Infection—Lovastatin—atherosclerosis	0.000151	0.00118	CcSEcCtD
Naproxen—Vision blurred—Niacin—atherosclerosis	0.00015	0.00117	CcSEcCtD
Naproxen—Confusional state—Ezetimibe—atherosclerosis	0.00015	0.00117	CcSEcCtD
Naproxen—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000149	0.00116	CcSEcCtD
Naproxen—Thrombocytopenia—Lovastatin—atherosclerosis	0.000149	0.00116	CcSEcCtD
Naproxen—Vision blurred—Pravastatin—atherosclerosis	0.000148	0.00116	CcSEcCtD
Naproxen—Myalgia—Simvastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Chest pain—Simvastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Arthralgia—Simvastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Infection—Ezetimibe—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Anxiety—Simvastatin—atherosclerosis	0.000148	0.00115	CcSEcCtD
Naproxen—Tremor—Pravastatin—atherosclerosis	0.000147	0.00115	CcSEcCtD
Naproxen—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Discomfort—Simvastatin—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Nervous system disorder—Ezetimibe—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Angioedema—Niacin—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Ill-defined disorder—Pravastatin—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000146	0.00114	CcSEcCtD
Naproxen—Anaemia—Pravastatin—atherosclerosis	0.000145	0.00113	CcSEcCtD
Naproxen—Anorexia—Lovastatin—atherosclerosis	0.000145	0.00113	CcSEcCtD
Naproxen—Skin disorder—Ezetimibe—atherosclerosis	0.000145	0.00113	CcSEcCtD
Naproxen—Angioedema—Pravastatin—atherosclerosis	0.000144	0.00112	CcSEcCtD
Naproxen—Vertigo—Niacin—atherosclerosis	0.000143	0.00112	CcSEcCtD
Naproxen—Syncope—Niacin—atherosclerosis	0.000143	0.00112	CcSEcCtD
Naproxen—Confusional state—Simvastatin—atherosclerosis	0.000143	0.00112	CcSEcCtD
Naproxen—Leukopenia—Niacin—atherosclerosis	0.000143	0.00111	CcSEcCtD
Naproxen—Urticaria—Rosuvastatin—atherosclerosis	0.000142	0.00111	CcSEcCtD
Naproxen—Oedema—Simvastatin—atherosclerosis	0.000142	0.00111	CcSEcCtD
Naproxen—Anaphylactic shock—Simvastatin—atherosclerosis	0.000142	0.00111	CcSEcCtD
Naproxen—Malaise—Pravastatin—atherosclerosis	0.000142	0.00111	CcSEcCtD
Naproxen—Abdominal pain—Rosuvastatin—atherosclerosis	0.000142	0.0011	CcSEcCtD
Naproxen—Vertigo—Pravastatin—atherosclerosis	0.000141	0.0011	CcSEcCtD
Naproxen—Palpitations—Niacin—atherosclerosis	0.000141	0.0011	CcSEcCtD
Naproxen—Infection—Simvastatin—atherosclerosis	0.000141	0.0011	CcSEcCtD
Naproxen—Leukopenia—Pravastatin—atherosclerosis	0.000141	0.0011	CcSEcCtD
Naproxen—Loss of consciousness—Niacin—atherosclerosis	0.00014	0.00109	CcSEcCtD
Naproxen—Cough—Niacin—atherosclerosis	0.000139	0.00109	CcSEcCtD
Naproxen—Thrombocytopenia—Simvastatin—atherosclerosis	0.000139	0.00108	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000138	0.00108	CcSEcCtD
Naproxen—Insomnia—Lovastatin—atherosclerosis	0.000137	0.00107	CcSEcCtD
Naproxen—Cough—Pravastatin—atherosclerosis	0.000137	0.00107	CcSEcCtD
Naproxen—Paraesthesia—Lovastatin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Naproxen—Arthralgia—Niacin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Naproxen—Myalgia—Niacin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Naproxen—Hypertension—Pravastatin—atherosclerosis	0.000136	0.00106	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000136	0.00106	CcSEcCtD
Naproxen—Anorexia—Simvastatin—atherosclerosis	0.000135	0.00105	CcSEcCtD
Naproxen—Dyspnoea—Lovastatin—atherosclerosis	0.000135	0.00105	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000135	0.00105	CcSEcCtD
Naproxen—Insomnia—Ezetimibe—atherosclerosis	0.000135	0.00105	CcSEcCtD
Naproxen—Arthralgia—Pravastatin—atherosclerosis	0.000134	0.00104	CcSEcCtD
Naproxen—Chest pain—Pravastatin—atherosclerosis	0.000134	0.00104	CcSEcCtD
Naproxen—Myalgia—Pravastatin—atherosclerosis	0.000134	0.00104	CcSEcCtD
Naproxen—Paraesthesia—Ezetimibe—atherosclerosis	0.000134	0.00104	CcSEcCtD
Naproxen—Dyspepsia—Lovastatin—atherosclerosis	0.000134	0.00104	CcSEcCtD
Naproxen—Anxiety—Pravastatin—atherosclerosis	0.000133	0.00104	CcSEcCtD
Naproxen—Dry mouth—Niacin—atherosclerosis	0.000133	0.00104	CcSEcCtD
Naproxen—Dyspnoea—Ezetimibe—atherosclerosis	0.000133	0.00103	CcSEcCtD
Naproxen—Discomfort—Pravastatin—atherosclerosis	0.000132	0.00103	CcSEcCtD
Naproxen—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000132	0.00103	CcSEcCtD
Naproxen—Decreased appetite—Lovastatin—atherosclerosis	0.000132	0.00103	CcSEcCtD
Naproxen—Dyspepsia—Ezetimibe—atherosclerosis	0.000131	0.00102	CcSEcCtD
Naproxen—Fatigue—Lovastatin—atherosclerosis	0.000131	0.00102	CcSEcCtD
Naproxen—Anaphylactic shock—Niacin—atherosclerosis	0.00013	0.00102	CcSEcCtD
Naproxen—Oedema—Niacin—atherosclerosis	0.00013	0.00102	CcSEcCtD
Naproxen—Constipation—Lovastatin—atherosclerosis	0.00013	0.00101	CcSEcCtD
Naproxen—Pain—Lovastatin—atherosclerosis	0.00013	0.00101	CcSEcCtD
Naproxen—Confusional state—Pravastatin—atherosclerosis	0.000129	0.00101	CcSEcCtD
Naproxen—Decreased appetite—Ezetimibe—atherosclerosis	0.000129	0.00101	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000129	0.00101	CcSEcCtD
Naproxen—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Asthenia—Rosuvastatin—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Insomnia—Simvastatin—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Oedema—Pravastatin—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Anaphylactic shock—Pravastatin—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Fatigue—Ezetimibe—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Shock—Niacin—atherosclerosis	0.000128	0.001	CcSEcCtD
Naproxen—Infection—Pravastatin—atherosclerosis	0.000127	0.000994	CcSEcCtD
Naproxen—Ibuprofen—PPARG—atherosclerosis	0.000127	0.0278	CrCbGaD
Naproxen—Paraesthesia—Simvastatin—atherosclerosis	0.000127	0.000994	CcSEcCtD
Naproxen—Constipation—Ezetimibe—atherosclerosis	0.000127	0.000992	CcSEcCtD
Naproxen—Pain—Ezetimibe—atherosclerosis	0.000127	0.000992	CcSEcCtD
Naproxen—Tachycardia—Niacin—atherosclerosis	0.000127	0.000992	CcSEcCtD
Naproxen—Pruritus—Rosuvastatin—atherosclerosis	0.000127	0.000988	CcSEcCtD
Naproxen—Skin disorder—Niacin—atherosclerosis	0.000127	0.000987	CcSEcCtD
Naproxen—Dyspnoea—Simvastatin—atherosclerosis	0.000127	0.000987	CcSEcCtD
Naproxen—Hyperhidrosis—Niacin—atherosclerosis	0.000126	0.000982	CcSEcCtD
Naproxen—Thrombocytopenia—Pravastatin—atherosclerosis	0.000126	0.00098	CcSEcCtD
Naproxen—Feeling abnormal—Lovastatin—atherosclerosis	0.000125	0.000975	CcSEcCtD
Naproxen—Dyspepsia—Simvastatin—atherosclerosis	0.000125	0.000974	CcSEcCtD
Naproxen—Anorexia—Niacin—atherosclerosis	0.000124	0.000969	CcSEcCtD
Naproxen—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000124	0.000967	CcSEcCtD
Naproxen—Hyperhidrosis—Pravastatin—atherosclerosis	0.000124	0.000967	CcSEcCtD
Naproxen—Decreased appetite—Simvastatin—atherosclerosis	0.000123	0.000962	CcSEcCtD
Naproxen—Feeling abnormal—Ezetimibe—atherosclerosis	0.000123	0.000956	CcSEcCtD
Naproxen—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000123	0.000955	CcSEcCtD
Naproxen—Diarrhoea—Rosuvastatin—atherosclerosis	0.000122	0.000955	CcSEcCtD
Naproxen—Fatigue—Simvastatin—atherosclerosis	0.000122	0.000954	CcSEcCtD
Naproxen—Anorexia—Pravastatin—atherosclerosis	0.000122	0.000954	CcSEcCtD
Naproxen—PTGS1—connective tissue—atherosclerosis	0.000122	0.024	CbGeAlD
Naproxen—Hypotension—Niacin—atherosclerosis	0.000122	0.000949	CcSEcCtD
Naproxen—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000122	0.000949	CcSEcCtD
Naproxen—Constipation—Simvastatin—atherosclerosis	0.000121	0.000946	CcSEcCtD
Naproxen—Pain—Simvastatin—atherosclerosis	0.000121	0.000946	CcSEcCtD
Naproxen—Urticaria—Lovastatin—atherosclerosis	0.000121	0.00094	CcSEcCtD
Naproxen—Abdominal pain—Lovastatin—atherosclerosis	0.00012	0.000935	CcSEcCtD
Naproxen—Body temperature increased—Lovastatin—atherosclerosis	0.00012	0.000935	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000119	0.000926	CcSEcCtD
Naproxen—Dizziness—Rosuvastatin—atherosclerosis	0.000118	0.000923	CcSEcCtD
Naproxen—Urticaria—Ezetimibe—atherosclerosis	0.000118	0.000922	CcSEcCtD
Naproxen—Insomnia—Niacin—atherosclerosis	0.000118	0.000919	CcSEcCtD
Naproxen—Abdominal pain—Ezetimibe—atherosclerosis	0.000118	0.000917	CcSEcCtD
Naproxen—Body temperature increased—Ezetimibe—atherosclerosis	0.000118	0.000917	CcSEcCtD
Naproxen—Paraesthesia—Niacin—atherosclerosis	0.000117	0.000912	CcSEcCtD
Naproxen—Feeling abnormal—Simvastatin—atherosclerosis	0.000117	0.000912	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000117	0.000911	CcSEcCtD
Naproxen—PTGS2—connective tissue—atherosclerosis	0.000117	0.023	CbGeAlD
Naproxen—CYP2C9—cardiovascular system—atherosclerosis	0.000117	0.0229	CbGeAlD
Naproxen—Dyspnoea—Niacin—atherosclerosis	0.000116	0.000906	CcSEcCtD
Naproxen—SLCO1A2—liver—atherosclerosis	0.000116	0.0228	CbGeAlD
Naproxen—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000116	0.000905	CcSEcCtD
Naproxen—Insomnia—Pravastatin—atherosclerosis	0.000116	0.000905	CcSEcCtD
Naproxen—Somnolence—Niacin—atherosclerosis	0.000116	0.000903	CcSEcCtD
Naproxen—ALB—liver—atherosclerosis	0.000115	0.0227	CbGeAlD
Naproxen—Paraesthesia—Pravastatin—atherosclerosis	0.000115	0.000898	CcSEcCtD
Naproxen—Dyspepsia—Niacin—atherosclerosis	0.000115	0.000894	CcSEcCtD
Naproxen—Dyspnoea—Pravastatin—atherosclerosis	0.000114	0.000892	CcSEcCtD
Naproxen—Decreased appetite—Niacin—atherosclerosis	0.000113	0.000883	CcSEcCtD
Naproxen—Dyspepsia—Pravastatin—atherosclerosis	0.000113	0.000881	CcSEcCtD
Naproxen—Rash—Rosuvastatin—atherosclerosis	0.000113	0.00088	CcSEcCtD
Naproxen—Dermatitis—Rosuvastatin—atherosclerosis	0.000113	0.000879	CcSEcCtD
Naproxen—Urticaria—Simvastatin—atherosclerosis	0.000113	0.000879	CcSEcCtD
Naproxen—Gastrointestinal disorder—Niacin—atherosclerosis	0.000113	0.000877	CcSEcCtD
Naproxen—Abdominal pain—Simvastatin—atherosclerosis	0.000112	0.000875	CcSEcCtD
Naproxen—Body temperature increased—Simvastatin—atherosclerosis	0.000112	0.000875	CcSEcCtD
Naproxen—Headache—Rosuvastatin—atherosclerosis	0.000112	0.000875	CcSEcCtD
Naproxen—Hypersensitivity—Lovastatin—atherosclerosis	0.000112	0.000872	CcSEcCtD
Naproxen—Decreased appetite—Pravastatin—atherosclerosis	0.000112	0.00087	CcSEcCtD
Naproxen—Pain—Niacin—atherosclerosis	0.000111	0.000869	CcSEcCtD
Naproxen—Fatigue—Pravastatin—atherosclerosis	0.000111	0.000863	CcSEcCtD
Naproxen—Pain—Pravastatin—atherosclerosis	0.00011	0.000855	CcSEcCtD
Naproxen—Constipation—Pravastatin—atherosclerosis	0.00011	0.000855	CcSEcCtD
Naproxen—Hypersensitivity—Ezetimibe—atherosclerosis	0.00011	0.000855	CcSEcCtD
Naproxen—Asthenia—Lovastatin—atherosclerosis	0.000109	0.000849	CcSEcCtD
Naproxen—Suprofen—PTGS2—atherosclerosis	0.000107	0.0235	CrCbGaD
Naproxen—Pruritus—Lovastatin—atherosclerosis	0.000107	0.000837	CcSEcCtD
Naproxen—Asthenia—Ezetimibe—atherosclerosis	0.000107	0.000833	CcSEcCtD
Naproxen—Gastrointestinal pain—Niacin—atherosclerosis	0.000107	0.000831	CcSEcCtD
Naproxen—PTGS1—cardiovascular system—atherosclerosis	0.000106	0.0209	CbGeAlD
Naproxen—Nausea—Rosuvastatin—atherosclerosis	0.000106	0.000829	CcSEcCtD
Naproxen—Feeling abnormal—Pravastatin—atherosclerosis	0.000106	0.000824	CcSEcCtD
Naproxen—Pruritus—Ezetimibe—atherosclerosis	0.000105	0.000821	CcSEcCtD
Naproxen—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000105	0.000818	CcSEcCtD
Naproxen—Hypersensitivity—Simvastatin—atherosclerosis	0.000105	0.000815	CcSEcCtD
Naproxen—Diarrhoea—Lovastatin—atherosclerosis	0.000104	0.000809	CcSEcCtD
Naproxen—Urticaria—Niacin—atherosclerosis	0.000104	0.000807	CcSEcCtD
Naproxen—Body temperature increased—Niacin—atherosclerosis	0.000103	0.000803	CcSEcCtD
Naproxen—Abdominal pain—Niacin—atherosclerosis	0.000103	0.000803	CcSEcCtD
Naproxen—Urticaria—Pravastatin—atherosclerosis	0.000102	0.000795	CcSEcCtD
Naproxen—Asthenia—Simvastatin—atherosclerosis	0.000102	0.000794	CcSEcCtD
Naproxen—Diarrhoea—Ezetimibe—atherosclerosis	0.000102	0.000794	CcSEcCtD
Naproxen—PTGS2—cardiovascular system—atherosclerosis	0.000102	0.02	CbGeAlD
Naproxen—Body temperature increased—Pravastatin—atherosclerosis	0.000101	0.000791	CcSEcCtD
Naproxen—Abdominal pain—Pravastatin—atherosclerosis	0.000101	0.000791	CcSEcCtD
Naproxen—Pruritus—Simvastatin—atherosclerosis	0.0001	0.000783	CcSEcCtD
Naproxen—Dizziness—Lovastatin—atherosclerosis	0.0001	0.000782	CcSEcCtD
Naproxen—Dizziness—Ezetimibe—atherosclerosis	9.84e-05	0.000767	CcSEcCtD
Naproxen—Diarrhoea—Simvastatin—atherosclerosis	9.71e-05	0.000757	CcSEcCtD
Naproxen—Vomiting—Lovastatin—atherosclerosis	9.65e-05	0.000752	CcSEcCtD
Naproxen—Hypersensitivity—Niacin—atherosclerosis	9.6e-05	0.000749	CcSEcCtD
Naproxen—Rash—Lovastatin—atherosclerosis	9.57e-05	0.000746	CcSEcCtD
Naproxen—Dermatitis—Lovastatin—atherosclerosis	9.56e-05	0.000745	CcSEcCtD
Naproxen—Headache—Lovastatin—atherosclerosis	9.5e-05	0.000741	CcSEcCtD
Naproxen—Vomiting—Ezetimibe—atherosclerosis	9.46e-05	0.000738	CcSEcCtD
Naproxen—Hypersensitivity—Pravastatin—atherosclerosis	9.45e-05	0.000737	CcSEcCtD
Naproxen—Dizziness—Simvastatin—atherosclerosis	9.38e-05	0.000732	CcSEcCtD
Naproxen—Rash—Ezetimibe—atherosclerosis	9.38e-05	0.000732	CcSEcCtD
Naproxen—PTGS1—adipose tissue—atherosclerosis	9.38e-05	0.0184	CbGeAlD
Naproxen—Dermatitis—Ezetimibe—atherosclerosis	9.37e-05	0.000731	CcSEcCtD
Naproxen—Asthenia—Niacin—atherosclerosis	9.35e-05	0.000729	CcSEcCtD
Naproxen—Headache—Ezetimibe—atherosclerosis	9.32e-05	0.000727	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—atherosclerosis	9.26e-05	0.0202	CrCbGaD
Naproxen—Pruritus—Niacin—atherosclerosis	9.22e-05	0.000719	CcSEcCtD
Naproxen—Asthenia—Pravastatin—atherosclerosis	9.21e-05	0.000718	CcSEcCtD
Naproxen—Pruritus—Pravastatin—atherosclerosis	9.08e-05	0.000708	CcSEcCtD
Naproxen—Vomiting—Simvastatin—atherosclerosis	9.02e-05	0.000704	CcSEcCtD
Naproxen—Nausea—Lovastatin—atherosclerosis	9.01e-05	0.000703	CcSEcCtD
Naproxen—PTGS2—adipose tissue—atherosclerosis	8.97e-05	0.0176	CbGeAlD
Naproxen—Rash—Simvastatin—atherosclerosis	8.95e-05	0.000698	CcSEcCtD
Naproxen—Dermatitis—Simvastatin—atherosclerosis	8.94e-05	0.000697	CcSEcCtD
Naproxen—Diarrhoea—Niacin—atherosclerosis	8.92e-05	0.000695	CcSEcCtD
Naproxen—Headache—Simvastatin—atherosclerosis	8.89e-05	0.000693	CcSEcCtD
Naproxen—Nausea—Ezetimibe—atherosclerosis	8.84e-05	0.000689	CcSEcCtD
Naproxen—Diarrhoea—Pravastatin—atherosclerosis	8.78e-05	0.000684	CcSEcCtD
Naproxen—Dizziness—Niacin—atherosclerosis	8.62e-05	0.000672	CcSEcCtD
Naproxen—Dizziness—Pravastatin—atherosclerosis	8.48e-05	0.000662	CcSEcCtD
Naproxen—Nausea—Simvastatin—atherosclerosis	8.43e-05	0.000657	CcSEcCtD
Naproxen—Vomiting—Niacin—atherosclerosis	8.29e-05	0.000646	CcSEcCtD
Naproxen—Fenoprofen—ALB—atherosclerosis	8.25e-05	0.018	CrCbGaD
Naproxen—Rash—Niacin—atherosclerosis	8.22e-05	0.000641	CcSEcCtD
Naproxen—Dermatitis—Niacin—atherosclerosis	8.21e-05	0.00064	CcSEcCtD
Naproxen—Headache—Niacin—atherosclerosis	8.16e-05	0.000637	CcSEcCtD
Naproxen—Vomiting—Pravastatin—atherosclerosis	8.16e-05	0.000636	CcSEcCtD
Naproxen—CYP2C8—liver—atherosclerosis	8.11e-05	0.0159	CbGeAlD
Naproxen—Rash—Pravastatin—atherosclerosis	8.09e-05	0.000631	CcSEcCtD
Naproxen—Dermatitis—Pravastatin—atherosclerosis	8.08e-05	0.00063	CcSEcCtD
Naproxen—Headache—Pravastatin—atherosclerosis	8.04e-05	0.000627	CcSEcCtD
Naproxen—Nausea—Niacin—atherosclerosis	7.74e-05	0.000604	CcSEcCtD
Naproxen—Nausea—Pravastatin—atherosclerosis	7.62e-05	0.000594	CcSEcCtD
Naproxen—CYP1A2—liver—atherosclerosis	7.59e-05	0.0149	CbGeAlD
Naproxen—CYP2C9—liver—atherosclerosis	7.21e-05	0.0142	CbGeAlD
Naproxen—Indomethacin—PTGS2—atherosclerosis	6.83e-05	0.0149	CrCbGaD
Naproxen—PTGS2—liver—atherosclerosis	6.29e-05	0.0124	CbGeAlD
Naproxen—Indomethacin—ALB—atherosclerosis	6.09e-05	0.0133	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—atherosclerosis	6.04e-05	0.0132	CrCbGaD
Naproxen—Ketoprofen—PTGS2—atherosclerosis	5.47e-05	0.0119	CrCbGaD
Naproxen—Flurbiprofen—ALB—atherosclerosis	5.38e-05	0.0118	CrCbGaD
Naproxen—Ibuprofen—PTGS2—atherosclerosis	5.38e-05	0.0117	CrCbGaD
Naproxen—Ketoprofen—ALB—atherosclerosis	4.87e-05	0.0106	CrCbGaD
Naproxen—Ibuprofen—ALB—atherosclerosis	4.79e-05	0.0105	CrCbGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	6.87e-06	8.28e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APOA1—atherosclerosis	6.86e-06	8.27e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LPA—atherosclerosis	6.83e-06	8.23e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARA—atherosclerosis	6.83e-06	8.22e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—INS—atherosclerosis	6.81e-06	8.21e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—atherosclerosis	6.74e-06	8.12e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NAMPT—atherosclerosis	6.71e-06	8.09e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NAMPT—atherosclerosis	6.67e-06	8.04e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.67e-06	8.04e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—LIPC—atherosclerosis	6.67e-06	8.03e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	6.66e-06	8.02e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.63e-06	7.99e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—LIPC—atherosclerosis	6.63e-06	7.99e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOC3—atherosclerosis	6.63e-06	7.98e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BGN—atherosclerosis	6.62e-06	7.97e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AGT—atherosclerosis	6.61e-06	7.97e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOB—atherosclerosis	6.6e-06	7.95e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOC3—atherosclerosis	6.59e-06	7.94e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—LDLR—atherosclerosis	6.59e-06	7.94e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	6.57e-06	7.91e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SERPINE1—atherosclerosis	6.57e-06	7.91e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOA5—atherosclerosis	6.55e-06	7.89e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—LDLR—atherosclerosis	6.55e-06	7.89e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOE—atherosclerosis	6.48e-06	7.8e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP27A1—atherosclerosis	6.46e-06	7.78e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CETP—atherosclerosis	6.43e-06	7.75e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTM1—atherosclerosis	6.42e-06	7.73e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CAV1—atherosclerosis	6.42e-06	7.73e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOA1—atherosclerosis	6.4e-06	7.72e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CETP—atherosclerosis	6.4e-06	7.71e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCA1—atherosclerosis	6.37e-06	7.68e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.36e-06	7.67e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	6.36e-06	7.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	6.31e-06	7.6e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—LPL—atherosclerosis	6.3e-06	7.59e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS3—atherosclerosis	6.27e-06	7.55e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CG—atherosclerosis	6.27e-06	7.55e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOB—atherosclerosis	6.26e-06	7.54e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—atherosclerosis	6.24e-06	7.52e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	6.23e-06	7.51e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	6.2e-06	7.47e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	6.18e-06	7.44e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	6.16e-06	7.42e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SCARB1—atherosclerosis	6.16e-06	7.42e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GPX1—atherosclerosis	6.15e-06	7.41e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—SCARB1—atherosclerosis	6.13e-06	7.38e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOA2—atherosclerosis	6.12e-06	7.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	6.12e-06	7.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALOX15—atherosclerosis	6.12e-06	7.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	6.12e-06	7.37e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—atherosclerosis	6.1e-06	7.35e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALOX5—atherosclerosis	6.09e-06	7.34e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—atherosclerosis	6.05e-06	7.28e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCG5—atherosclerosis	6.05e-06	7.28e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	6.04e-06	7.27e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NFKB1—atherosclerosis	6.03e-06	7.27e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6e-06	7.23e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CD36—atherosclerosis	5.99e-06	7.21e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—NOS3—atherosclerosis	5.97e-06	7.2e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—LPL—atherosclerosis	5.97e-06	7.19e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—INS—atherosclerosis	5.93e-06	7.14e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK8—atherosclerosis	5.93e-06	7.14e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CG—atherosclerosis	5.85e-06	7.04e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LPA—atherosclerosis	5.84e-06	7.03e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HMGCR—atherosclerosis	5.82e-06	7.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PRKCG—atherosclerosis	5.81e-06	7e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HMGCR—atherosclerosis	5.79e-06	6.97e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—MTHFR—atherosclerosis	5.67e-06	6.83e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BGN—atherosclerosis	5.65e-06	6.81e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—atherosclerosis	5.64e-06	6.8e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.63e-06	6.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	5.61e-06	6.76e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOA5—atherosclerosis	5.6e-06	6.74e-05	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	5.59e-06	6.73e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARA—atherosclerosis	5.57e-06	6.7e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—INS—atherosclerosis	5.54e-06	6.67e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—atherosclerosis	5.48e-06	6.6e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—HMOX1—atherosclerosis	5.47e-06	6.59e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—atherosclerosis	5.46e-06	6.58e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NAMPT—atherosclerosis	5.46e-06	6.58e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—atherosclerosis	5.44e-06	6.55e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	5.44e-06	6.55e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.43e-06	6.54e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LIPC—atherosclerosis	5.43e-06	6.54e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—atherosclerosis	5.42e-06	6.53e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—atherosclerosis	5.41e-06	6.52e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOC3—atherosclerosis	5.39e-06	6.5e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AGT—atherosclerosis	5.39e-06	6.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	5.39e-06	6.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTHFR—atherosclerosis	5.38e-06	6.48e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LDLR—atherosclerosis	5.36e-06	6.46e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	5.33e-06	6.42e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOE—atherosclerosis	5.28e-06	6.36e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	5.28e-06	6.36e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	5.27e-06	6.34e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.25e-06	6.32e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOB—atherosclerosis	5.24e-06	6.31e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CETP—atherosclerosis	5.24e-06	6.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PDGFB—atherosclerosis	5.23e-06	6.31e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CAV1—atherosclerosis	5.23e-06	6.3e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOA1—atherosclerosis	5.22e-06	6.29e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.22e-06	6.29e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALOX5—atherosclerosis	5.2e-06	6.27e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NOS3—atherosclerosis	5.2e-06	6.27e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCA1—atherosclerosis	5.19e-06	6.25e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—atherosclerosis	5.18e-06	6.24e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCA1—atherosclerosis	5.16e-06	6.21e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—atherosclerosis	5.1e-06	6.14e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—atherosclerosis	5.07e-06	6.11e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—atherosclerosis	5.03e-06	6.05e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SCARB1—atherosclerosis	5.02e-06	6.04e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOE—atherosclerosis	5.01e-06	6.03e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—LPL—atherosclerosis	5e-06	6.03e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—atherosclerosis	4.99e-06	6.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CAV1—atherosclerosis	4.96e-06	5.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOA1—atherosclerosis	4.95e-06	5.96e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	4.88e-06	5.88e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPX1—atherosclerosis	4.88e-06	5.88e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NOS3—atherosclerosis	4.85e-06	5.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	4.81e-06	5.79e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—atherosclerosis	4.77e-06	5.74e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—atherosclerosis	4.76e-06	5.73e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CD36—atherosclerosis	4.75e-06	5.73e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HMGCR—atherosclerosis	4.74e-06	5.71e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NAMPT—atherosclerosis	4.67e-06	5.62e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—atherosclerosis	4.67e-06	5.62e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	4.64e-06	5.59e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LIPC—atherosclerosis	4.64e-06	5.59e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOC3—atherosclerosis	4.61e-06	5.55e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—atherosclerosis	4.6e-06	5.54e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LDLR—atherosclerosis	4.58e-06	5.52e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—atherosclerosis	4.52e-06	5.44e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—INS—atherosclerosis	4.51e-06	5.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MTHFR—atherosclerosis	4.5e-06	5.43e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CETP—atherosclerosis	4.48e-06	5.39e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HMOX1—atherosclerosis	4.45e-06	5.36e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—atherosclerosis	4.44e-06	5.35e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HMOX1—atherosclerosis	4.42e-06	5.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARA—atherosclerosis	4.42e-06	5.32e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SCARB1—atherosclerosis	4.29e-06	5.16e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AGT—atherosclerosis	4.28e-06	5.15e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—INS—atherosclerosis	4.28e-06	5.15e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.27e-06	5.15e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—atherosclerosis	4.27e-06	5.15e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOB—atherosclerosis	4.26e-06	5.13e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOB—atherosclerosis	4.24e-06	5.11e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCA1—atherosclerosis	4.22e-06	5.09e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOE—atherosclerosis	4.19e-06	5.05e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—atherosclerosis	4.18e-06	5.03e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	4.17e-06	5.03e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CAV1—atherosclerosis	4.15e-06	5e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—atherosclerosis	4.15e-06	4.99e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOA1—atherosclerosis	4.14e-06	4.99e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—atherosclerosis	4.14e-06	4.99e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—atherosclerosis	4.14e-06	4.98e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—atherosclerosis	4.12e-06	4.97e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—LPL—atherosclerosis	4.07e-06	4.9e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HMGCR—atherosclerosis	4.05e-06	4.88e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—LPL—atherosclerosis	4.05e-06	4.87e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPX1—atherosclerosis	3.97e-06	4.78e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NOS3—atherosclerosis	3.96e-06	4.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPX1—atherosclerosis	3.95e-06	4.76e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SERPINE1—atherosclerosis	3.93e-06	4.73e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CD36—atherosclerosis	3.87e-06	4.66e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CD36—atherosclerosis	3.85e-06	4.63e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—atherosclerosis	3.79e-06	4.56e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—atherosclerosis	3.78e-06	4.56e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS3—atherosclerosis	3.75e-06	4.52e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTHFR—atherosclerosis	3.66e-06	4.41e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—atherosclerosis	3.65e-06	4.4e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	3.65e-06	4.4e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTHFR—atherosclerosis	3.64e-06	4.39e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HMOX1—atherosclerosis	3.62e-06	4.36e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—atherosclerosis	3.62e-06	4.36e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCA1—atherosclerosis	3.61e-06	4.35e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARA—atherosclerosis	3.6e-06	4.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—INS—atherosclerosis	3.58e-06	4.31e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARA—atherosclerosis	3.57e-06	4.31e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—atherosclerosis	3.49e-06	4.21e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AGT—atherosclerosis	3.48e-06	4.19e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOB—atherosclerosis	3.47e-06	4.18e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AGT—atherosclerosis	3.46e-06	4.17e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOE—atherosclerosis	3.41e-06	4.11e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOE—atherosclerosis	3.39e-06	4.09e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CAV1—atherosclerosis	3.38e-06	4.07e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—atherosclerosis	3.37e-06	4.07e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOA1—atherosclerosis	3.37e-06	4.06e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CAV1—atherosclerosis	3.36e-06	4.05e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOA1—atherosclerosis	3.35e-06	4.04e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LPL—atherosclerosis	3.31e-06	3.99e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—atherosclerosis	3.28e-06	3.96e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GPX1—atherosclerosis	3.23e-06	3.89e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CD36—atherosclerosis	3.15e-06	3.79e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NOS3—atherosclerosis	3.14e-06	3.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.09e-06	3.73e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—atherosclerosis	3.08e-06	3.71e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—atherosclerosis	3.06e-06	3.69e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTHFR—atherosclerosis	2.98e-06	3.59e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—atherosclerosis	2.97e-06	3.58e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOB—atherosclerosis	2.96e-06	3.57e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—atherosclerosis	2.95e-06	3.56e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARA—atherosclerosis	2.93e-06	3.52e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—INS—atherosclerosis	2.91e-06	3.51e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—INS—atherosclerosis	2.9e-06	3.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.88e-06	3.47e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—atherosclerosis	2.88e-06	3.47e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AGT—atherosclerosis	2.83e-06	3.41e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LPL—atherosclerosis	2.83e-06	3.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOE—atherosclerosis	2.78e-06	3.34e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPX1—atherosclerosis	2.76e-06	3.33e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CAV1—atherosclerosis	2.75e-06	3.31e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—atherosclerosis	2.75e-06	3.31e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOA1—atherosclerosis	2.74e-06	3.31e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CD36—atherosclerosis	2.69e-06	3.24e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—atherosclerosis	2.68e-06	3.22e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—atherosclerosis	2.67e-06	3.22e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—atherosclerosis	2.56e-06	3.08e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NOS3—atherosclerosis	2.56e-06	3.08e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTHFR—atherosclerosis	2.55e-06	3.07e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NOS3—atherosclerosis	2.54e-06	3.06e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—atherosclerosis	2.51e-06	3.02e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARA—atherosclerosis	2.5e-06	3.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—atherosclerosis	2.48e-06	2.99e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AGT—atherosclerosis	2.42e-06	2.92e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—atherosclerosis	2.42e-06	2.91e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—atherosclerosis	2.39e-06	2.88e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOE—atherosclerosis	2.37e-06	2.86e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—INS—atherosclerosis	2.37e-06	2.86e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CAV1—atherosclerosis	2.35e-06	2.83e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOA1—atherosclerosis	2.35e-06	2.83e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—atherosclerosis	2.34e-06	2.82e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—atherosclerosis	2.32e-06	2.8e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—atherosclerosis	2.23e-06	2.69e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—atherosclerosis	2.17e-06	2.62e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.14e-06	2.58e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NOS3—atherosclerosis	2.08e-06	2.51e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—atherosclerosis	2.07e-06	2.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—INS—atherosclerosis	2.03e-06	2.44e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.9e-06	2.29e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—atherosclerosis	1.87e-06	2.25e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—atherosclerosis	1.86e-06	2.24e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—atherosclerosis	1.82e-06	2.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NOS3—atherosclerosis	1.78e-06	2.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—atherosclerosis	1.72e-06	2.08e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.63e-06	1.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—atherosclerosis	1.44e-06	1.74e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—atherosclerosis	1.17e-06	1.42e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—atherosclerosis	1.17e-06	1.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—atherosclerosis	9.56e-07	1.15e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—atherosclerosis	8.17e-07	9.84e-06	CbGpPWpGaD
